Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2benzinga_article·Jul 23 at 01:06 PMPALI+0.26%
This Signet Jewelers Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursdaybenzinga_article·Jul 23 at 06:29 AMPALI+0.26%SIG+2.56%
Palisade Bio, Inc. (NASDAQ:PALI) Given Average Recommendation of "Buy" by AnalystsMarket Beat·Jul 20 at 03:14 AMPALI+0.26%
Palisade Bio director Robert Baltera Jr acquires USD 88,687.50 in common sharesPUBT·Jul 10 at 05:15 PMPALI+0.26%
Palisade Bio to meet investors at Leerink Partners Therapeutics Forum July 14-15PUBT·Jul 10 at 08:00 AMPALI+0.26%
Palisade Bio director Robert Baltera Jr. acquires USD 101,044 of common sharesPUBT·Jul 8 at 05:56 PMPALI+0.26%
Palisade Bio director Robert Baltera Jr acquires USD 59,400 in common sharesPUBT·Jul 6 at 06:49 PMPALI+0.26%
Palisade Bio shares are trading higher after FDA approval of its Investigational New Drug application for PALI-2108, which allows the company to start its Phase 2 ASCENTRA-UC trial in patients with ulcerative colitis.benzinga_article·Jun 29 at 12:28 PMPALI+0.26%
Palisade Bio wins FDA IND clearance for PALI-2108 ulcerative colitis trialPUBT·Jun 29 at 07:31 AMPALI+0.26%
Palisade Bio director Robert Baltera Jr. files initial beneficial ownership statementPUBT·Jun 18 at 03:06 PMPALI+0.26%
Palisade Bio Shareholders Approve Charter Amendments, Governance MattersTip Ranks·Jun 11 at 05:53 PMPALI+0.26%
PALISA appoints Jordan Zwick to its Board and Audit CommitteeTradingView·Jun 11 at 04:33 PMPALI+0.26%
